Original article—alimentary tract
Variations in Presentations of Esophageal Involvement in Lichen Planus

https://doi.org/10.1016/j.cgh.2010.04.024Get rights and content

Background & Aims

Lichen planus is a relatively uncommon, presumed autoimmune disease that affects middle-aged patients and is manifested in the skin, nails, and mucous membranes. Reports of esophageal involvement have been rare, despite the classification of the esophagus as a mucous membrane.

Methods

Assuming esophageal involvement might not be as rare as expected, we reviewed the Mayo Clinic Pathology Database for all cases from 2000 to the present.

Results

Twenty-seven cases were identified, with a mean age of 64 years; 25 were women. Patients presenting with esophageal lichen planus as the initial manifestation and those with a diagnosis of lichen planus involving other sites were equal in number. Many patients had received multiple dilations and reflux treatments before diagnosis. All patients presented with dysphagia. Endoscopy and radiology studies demonstrated a wide range of abnormalities, including strictures of varying length and location, small-caliber esophagus, and a mucosal appearance of sloughing, white discoloration, erythema, thickening, and superficial ulceration. Treatment regimens varied markedly, with some patients responding to topical or systemic corticosteroids.

Conclusions

Esophageal lichen planus is rare but probably more common than previously suspected. It presents with a wide range of endoscopic signs and is commonly the presenting sign of lichen planus. In evaluating middle-aged patients with strictures, particularly proximal esophageal strictures in women, physicians should consider a diagnosis of lichen planus even in the absence of extraesophageal manifestations.

Section snippets

Methods

The Mayo pathology database was searched for all patients with findings consistent with lichen planus on esophageal biopsy between 2000 and 2009. Histologic findings that were considered consistent with lichen planus were lichenoid lymphocytic infiltrate, damage to the basal layer of the epithelium, and necrotic keratinocytes (Civatte bodies). The biopsies were all reviewed by one pathologist (T.S.). The following clinical data were then extracted from the patients' charts: age, sex, type and

Demographics and Symptoms

Twenty-five patients were women, and 2 patients were men (Table 1). The age range was 50–76 years, with a median age of 64. No patients had a history or tested positive for hepatitis C virus. All 27 patients noted solid food dysphagia as their dominant symptom of esophageal disease. Two patients also complained of odynophagia. The severity was variable, with some patients having intermittent symptoms whereas others had symptoms at every meal including 2 patients who were avoiding all solid food

Discussion

This is the largest series reported on patients with symptomatic involvement of the esophagus by lichen planus. As a result, several conclusions can be drawn concerning this disease. (1) Esophageal involvement by lichen planus is rare but might be more prevalent than previously described. (2) Esophageal lichen planus is highly variable in terms of its association to extraesophageal disease and its ability to present as the initial manifestation of lichen planus. (3) There is typically a long

References (27)

  • Sheehan-Dare RA, Cotterill JA, Simmons AV. Oesophageal lichen planus. Br J Dermatol...
  • F. Quevrin et al.

    Lichen plan plurimuqueux et atteinte oesophagienne

    Sem Hop Paris

    (1986)
  • A. Bousser et al.

    Lichen plan et stenose oesophagienne: a propos d'un cas

    Ann Derm Venereol

    (1986)
  • Cited by (68)

    • Non eosinophilic chronic stricturing esophagitis: Lessons from thirty eight cases

      2023, Clinics and Research in Hepatology and Gastroenterology
    • Coexistence of oral lichen planus and vulvar lichen sclerosus

      2023, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
    View all citing articles on Scopus

    Conflicts of interest The authors disclose the following: Jeffrey A. Alexander received support from Glaxo Smith Kline, Merck, and Novartis and is a consultant for Wyeth and Meritage. The remaining authors disclose no conflicts.

    View full text